-
Something wrong with this record ?
Evaluation of total adiponectin, adipocyte fatty acid binding protein and fibroblast growth factor 21 levels in individuals with metabolic syndrome
D. Novotný, H. Vaverková, D. Karásek, J. Lukeš, L. Slavík, P. Malina, J. Orság
Language English Country Czech Republic
Document type Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Adiponectin blood MeSH
- Asymptomatic Diseases MeSH
- Biomarkers blood MeSH
- Adult MeSH
- Dyslipidemias blood diagnosis MeSH
- Fibroblast Growth Factors blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Metabolic Syndrome blood diagnosis MeSH
- Fatty Acid-Binding Proteins blood MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Evaluation Study MeSH
- Research Support, Non-U.S. Gov't MeSH
Although many studies have investigated the relationships of several adipokines to metabolic syndrome (MetS), the interrelationships of adiponectin (ADP), adipocyte fatty acid binding protein (A-FABP) and fibroblast growth factor 21 (FGF 21) have not been described in detail. We examined 209 asymptomatic dyslipidemic patients divided into MetS+ (n=73) and MetS- (n=136) groups. The aim of study was to evaluate the relationships between observed adipokines, to compare the levels of total ADP, A-FABP and FGF 21 in individuals with and without MetS, and to elucidate the relationships of individual adipokines to lipid parameters, markers of insulin resistance and endothelial hemostatic markers in these groups. In MetS+ group, we found the independent positive association ADP with A-FABP (beta=0.4888, p=0.0382), A-FABP with FGF 21 (beta=0.3811, p=0.0002) and von Willebrand factor (beta=0.4502, p=0.0013), and FGF 21 with A-FABP (beta=0.4422, p=0.0002). Our study has confirmed the well-established risk profile of subjects with MetS, although clinically asymptomatic. MetS+ patients had also lower levels of ADP and higher levels of A-FABP and FGF 21. Our study evaluated the interrelationships of ADP, A-FABP and FGF 21 in asymptomatic dyslipidemic subjects with diagnosis of MetS. Especially strong association between A-FABP and FGF 21 needs to be clarified in further studies.
Department of Clinical Biochemistry Hospital Písek Písek Czech Republic
Department of Clinical Biochemistry University Hospital Olomouc Olomouc Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15003893
- 003
- CZ-PrNML
- 005
- 20150129124535.0
- 007
- ta
- 008
- 150128s2014 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.932602 $2 doi
- 035 __
- $a (PubMed)24397811
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Novotný, Dalibor, $d 1965-2015 $7 xx0041926 $u Department of Clinical Biochemistry, University Hospital Olomouc, Olomouc, Czech Republic
- 245 10
- $a Evaluation of total adiponectin, adipocyte fatty acid binding protein and fibroblast growth factor 21 levels in individuals with metabolic syndrome / $c D. Novotný, H. Vaverková, D. Karásek, J. Lukeš, L. Slavík, P. Malina, J. Orság
- 520 9_
- $a Although many studies have investigated the relationships of several adipokines to metabolic syndrome (MetS), the interrelationships of adiponectin (ADP), adipocyte fatty acid binding protein (A-FABP) and fibroblast growth factor 21 (FGF 21) have not been described in detail. We examined 209 asymptomatic dyslipidemic patients divided into MetS+ (n=73) and MetS- (n=136) groups. The aim of study was to evaluate the relationships between observed adipokines, to compare the levels of total ADP, A-FABP and FGF 21 in individuals with and without MetS, and to elucidate the relationships of individual adipokines to lipid parameters, markers of insulin resistance and endothelial hemostatic markers in these groups. In MetS+ group, we found the independent positive association ADP with A-FABP (beta=0.4888, p=0.0382), A-FABP with FGF 21 (beta=0.3811, p=0.0002) and von Willebrand factor (beta=0.4502, p=0.0013), and FGF 21 with A-FABP (beta=0.4422, p=0.0002). Our study has confirmed the well-established risk profile of subjects with MetS, although clinically asymptomatic. MetS+ patients had also lower levels of ADP and higher levels of A-FABP and FGF 21. Our study evaluated the interrelationships of ADP, A-FABP and FGF 21 in asymptomatic dyslipidemic subjects with diagnosis of MetS. Especially strong association between A-FABP and FGF 21 needs to be clarified in further studies.
- 650 _2
- $a adiponektin $x krev $7 D052242
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a asymptomatické nemoci $7 D058070
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a dyslipidemie $x krev $x diagnóza $7 D050171
- 650 _2
- $a proteiny vázající mastné kyseliny $x krev $7 D050556
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fibroblastové růstové faktory $x krev $7 D005346
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metabolický syndrom $x krev $x diagnóza $7 D024821
- 650 _2
- $a lidé středního věku $7 D008875
- 655 _2
- $a hodnotící studie $7 D023362
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vaverková, Helena, $d 1942- $7 nlk20000083882 $u Third Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Karásek, David $7 stk2007415300 $u Third Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Lukeš, Jiří $7 xx0070976 $u Department of Clinical Biochemistry, University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Slavík, Luděk $7 xx0081908 $u Department of HematoOncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Malina, Pavel $7 xx0158428 $u Department of Clinical Biochemistry, Hospital Písek, Písek, Czech Republic
- 700 1_
- $a Orság, Jiří $7 xx0229430 $u Third Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 63, č. 2 (2014), s. 219-228
- 856 41
- $u http://www.biomed.cas.cz/physiolres/ $y domovská stránka časopisu
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 4 $z 0
- 990 __
- $a 20150128 $b ABA008
- 991 __
- $a 20150129124729 $b ABA008
- 999 __
- $a ok $b bmc $g 1060953 $s 886648
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 63 $c 2 $d 219-228 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- LZP __
- $b NLK118 $a Pubmed-20150128